Macro Biologics Carlsbad, CA, USA
NEXT-GENERATION LOCAL ANTIMICROBIAL
Direct-Acting Large Molecule Therapeutic; Topical
Macro Biologics (formerly known as Amicrobe) is developing a large molecule therapeutic, Amicidin-β, designed for direct application to tissues. Amicidin-β is a novel biological therapeutic (single chain amino acid polymer) that combines microbicidal activity and surfactant properties within the same molecule for enhanced intrawound performance. Built by iterative design and testing, Amicidin-β is being developed with CARB-X’s support for treatment of life-threatening focal infections, especially those involving foreign bodies and biofilms. High-impact applications may include infections associated with orthopedic implants, surgical procedures, and trauma, including emergency and post-disaster events. In June 2020, Macro Biologics extended the project to design and prototype a new formulation of the product for use in low- and middle-income countries (LMIC). Macro Biologics is a bioengineering company dedicated to the development of a new generation of products in the fight against antibiotic resistance.
Current Development Stage: Pre-Clinical
CARB-X Investment: Initial investment of up to $2.48m with potential option payments up to $3.76m. Additional $4.6m awarded June 2020 to support further development of Amicidin-β and development of extended formulation.
Initial CARB-X Investment Date: October 1, 2017